J H Beijnen

发表

PXR-mediated P-glycoprotein induction by small molecule tyrosine kinase inhibitors.

J. Schellens, J. Beijnen, I. Meijerman, 2013, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Phase I and pharmacokinetic study of oral paclitaxel.

J. Schellens, H. Rosing, J. Beijnen, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The functional role of P-glycoprotein in the blood-brain barrier.

J. Beijnen, O. van Tellingen, O. Tellingen, 1997, Journal of pharmaceutical sciences.

Pharmaceutical development and preliminary clinical testing of an oral solid dispersion formulation of docetaxel (ModraDoc001).

J. Schellens, J. Beijnen, A. Huitema, 2011, International journal of pharmaceutics.

The effect of plasma drug concentrations on HIV‐1 clearance rate during quadruple drug therapy

J W Mulder, H. Schuitemaker, J. Beijnen, 1998, AIDS.

Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL.

J. Beijnen, A. Sparreboom, O. van Tellingen, 1996, Cancer research.

Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: pharmacokinetics and cisplatin-DNA adduct formation in patients and ovarian cancer cell lines.

H. Bartelink, J. Beijnen, A. Begg, 1998, European journal of cancer.

Palliative effect of metaiodobenzylguanidine in metastatic carcinoid tumors.

J. Beijnen, H. Boot, B. Taal, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan.

J. Schellens, J. Beijnen, J. Schellens, 2000, Journal of the National Cancer Institute.

Oral topotecan: bioavailability and effect of food co-administration

J. Schellens, H. Rosing, J. Beijnen, 1999, British Journal of Cancer.

Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918.

F H Hausheer, J. Schellens, J. Beijnen, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase I and pharmacologic study of the combination paclitaxel and carboplatin as first-line chemotherapy in stage III and IV ovarian cancer.

S. Rodenhuis, H. Rosing, J. Beijnen, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients.

A. C. Dubbelman, H. Rosing, J. Beijnen, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

P-glycoprotein system as a determinant of drug interactions: the case of digoxin-verapamil.

J. Schellens, J. Beijnen, J H Beijnen, 1999, Pharmacological research.

Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918.

J. Schellens, H. Rosing, J. Beijnen, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Optimizing anticancer drug treatment in pregnant cancer patients: pharmacokinetic analysis of gestation-induced changes for doxorubicin, epirubicin, docetaxel and paclitaxel.

J. Schellens, J. Beijnen, F. Amant, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Development and validation of an assay for the simultaneous determination of zidovudine, abacavir, emtricitabine, lamivudine, tenofovir and ribavirin in human plasma using liquid chromatography-tandem mass spectrometry.

H. Rosing, J. Beijnen, J H Beijnen, 2013, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Altered pharmacokinetics of vinblastine in Mdr1a P-glycoprotein-deficient Mice.

J. Beijnen, P. Borst, O. van Tellingen, 1996, Journal of the National Cancer Institute.

Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833.

J. Beijnen, P. Borst, A. Schinkel, 1997, The Journal of clinical investigation.

Development of luciferase tagged brain tumour models in mice for chemotherapy intervention studies.

A Heerschap, A. Heerschap, J. Beijnen, 2006, European journal of cancer.

Tissue distribution, metabolism and excretion of paclitaxel in mice

J. Beijnen, A. Sparreboom, O. van Tellingen, 1996, Anti-cancer drugs.